1. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). (22nd March 2018) Authors: Bissonnette, R.; Luger, T.; Thaçi, D.; Toth, D.; Lacombe, A.; Xia, S.; Mazur, R.; Patekar, M.; Charef, P.; Milutinovic, M.; Leonardi, C.; Mrowietz, U. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 9(2018) Page Start: 1507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial. (19th January 2021) Authors: Bodemer, C.; Kaszuba, A.; Kingo, K.; Tsianakas, A.; Morita, A.; Rivas, E.; Papanastasiou, P.; Keefe, D.; Patekar, M.; Charef, P.; Zhang, L.; Cafoncelli, S.; Papavassilis, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 4(2021) Page Start: 938 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗